Epilepsy - Epidemiology Forecast - 2032

This ‘Epilepsy - Epidemiology Forecast - 2032' report delivers an in-depth understanding of epilepsy, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Epilepsy Understanding

Epilepsy is a chronic, non-communicable disease of the brain that affects people of all ages and contributes significantly to the global disease burden. It is a neurological disorder characterized by recurrent, unprovoked seizures. A seizure occurs when the brain has sudden and abnormal electrical activity. These abnormal electrical discharges may cause changes in behavior, consciousness, sensation, or a combination of these factors.

Furthermore, epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Temporary symptoms occur, such as loss of awareness or consciousness and disturbances of movement, sensation (including vision, hearing, and taste), mood, or other cognitive functions.

Epilepsy is classified based on various factors, including the underlying cause, the part of the brain where seizures originate, and the specific characteristics of that seizure. Such as generalized seizures (affect both sides of the brain), further subdivided into absence and tonic-clonic seizures.

Focal seizures (originate in a specific area of the brain) are further classified as simple focal seizures where the consciousness is maintained, with localized symptoms, complex focal seizures that include altered consciousness and complex, involuntary movements, and secondarily generalized seizures, these seizures last as long as few minutes. While absence seizures, as the name suggests, include brief lapses in consciousness with minimal or no movements, tonic-clonic seizures can be tiring as they include rapid blinking or a few seconds of staring into space, crying out loud, loss of consciousness along with muscle jerks and spasms in the patient.

Epilepsy Diagnosis

An early diagnosis of epilepsy is essential for preventing disease progression, timely intervention, and optimizing treatment management. Diagnosis typically involves a thorough medical evaluation, including a detailed history, physical examination, and various diagnostic tests are followed. Electrical activity and structural abnormalities in the brain can be measured using brain scans such as magnetic resonance imaging (MRI), electroencephalogram (EEG), or computed tomography. Blood tests are also performed to check for the underlying conditions causing epilepsy.

Epilepsy Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of epilepsy, gender-specific diagnosed prevalent cases of epilepsy, diagnosed prevalent cases of epilepsy based on seizure type, and diagnosed cases of other types of epilepsies and associated diseases in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Epilepsy Detailed Epidemiology Segmentation

• According to the publisher's estimates in 2022, the total diagnosed prevalent cases of epilepsy were nearly 7,001,492 in 2022, which is expected to increase by 2032.
• In 2022, among the 7MM, the US accounted for approximately 3,365,968 total diagnosed prevalent cases of epilepsy, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2032.
• As per the analysis, in 2022, the US had the highest number of cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
• In 2022, among the other types of epilepsies and associated diseases, the highest cases were found in highly drug-resistant focal epilepsy or drug-resistant epilepsy or refractory cases, i.e., around 267,342, while the least cases were found in CDKL5 deficiency disorder, around 1,671 in the US.
• In 2022, among EU4 and the UK, there were approximately 2,741,851 total diagnosed prevalent cases of epilepsy, of which nearly 1,277,563 were found in males, while around 1,464,287 cases were found in females. These cases are expected to change during the study period.
• Among EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of epilepsy, i.e., around 736,071, followed by France with approximately 713,856 cases, while Spain accounted for the least cases with approximately 340,609 in 2022.
• Among the 7MM, Japan accounted for the second-highest diagnosed prevalent cases of epilepsy in 2022, with approximately 893,673 cases. These cases are expected to change during the study period.
• In Japan, among the other types of epilepsies and associated diseases, the highest number of cases were found in drug-resistant epilepsy/refractory cases, approximately 82,810, followed by photosensitivity and childhood absence epilepsy with equal cases, i.e., around 44,684, in 2022. These cases are expected to change by 2032.

Scope of the Report

• The report covers a descriptive overview of epilepsy, explaining its symptoms, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of epilepsy.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalent cases of epilepsy, gender-specific diagnosed prevalent cases of epilepsy, diagnosed prevalent cases of epilepsy based on seizure type, and diagnosed cases of other types of epilepsies and associated diseases.

Report Highlights

• Ten Years Forecast of Epilepsy
• The 7MM Coverage
• Total Diagnosed Prevalent Cases of Epilepsy
• Gender-specific Diagnosed Prevalent Cases of Epilepsy
• Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type
• Diagnosed Cases of Other Types of Epilepsies and Associated Diseases

Key Questions Answered

• What are the disease risks and burdens of epilepsy?
• What is the historical epilepsy patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of epilepsy at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with epilepsy?
• Which country would have the highest diagnosed prevalent population of epilepsy among the countries mentioned above during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy

The Epilepsy report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM epilepsy epidemiology forecast.
• The epilepsy epidemiology report and model were written and developed by Master's and PhD-level epidemiologists.
• The epilepsy epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by Segmentation
• Factors Driving Growth in a Specific Patient Population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032